Nuvectis Pharma: An Interesting Early Pipeline Does Not Justify A Buy [Seeking Alpha]
Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference [Yahoo! Finance]
Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
Nuvectis Pharma, Inc. (NASDAQ: NVCT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights [Yahoo! Finance]